腮腺炎病毒抗血清的制备

以制备适用于疫苗生产检定中病毒鉴别试验和外源因子检查的高效价腮腺炎病毒抗血清为目的。用腮腺炎病毒接种SPF鸡胚尿囊腔,培养收取病毒尿液免疫SPF鸡,采集抗血清。腮腺炎病毒接种Vero细胞,培养病毒抗原经PEG沉淀,超速离心法纯化后免疫家兔采集抗血清。比较两种免疫方法所得病毒抗血清效价。结果显示SPF鸡抗腮腺炎病毒血清中和抗体GMT为1:1716,兔抗腮腺炎病毒血清中和抗体GMT为1:732。两种动物抗血清均适用于疫苗生产相关检定。免疫SPF鸡制备的病毒抗血清无特定病原及抗体污染,是毒种外源因子检测和疫苗鉴别试验的理想试剂。免疫SPF鸡制备病毒抗血清的程序简单,结果易于验证,有利于生物试剂标准化。     

双抗体夹心ELISA法检测养殖对虾病毒的研究

用纯化的长毛对虾球状病毒（PPSV）和日本对虾中肠腺坏死杆状病毒（BMNV）制备新西兰兔抗BMNV和抗PPSV抗血清及Balb／c小鼠抗BMNV和抗PPSV抗血清,建立检测PSV和BMNV的双抗体夹心ELISA检测法,结果表明,双抗体夹心ELISA法具有较高的灵敏度,可以从100μl待测组织匀浆液中检测到50ng的PPSV蛋白,以及100ng的BMNV蛋白。不同病毒抗血清无交叉反应性,用该ELISA技术检测养殖对虾和多种采自养殖虾池及其附近的近海岸生物,发现相当比例的外观正常的对虾和近海岸生物已呈阳性反应     

炭疽致死毒素中和试验检验标准

提出了一种毒素中和试验的操作细节标准。此实验室试验,测量含炭疽致死毒素抗体抗血清的特异性保护J774A．1细胞抗炭疽芽胞杆菌致死毒素的细胞毒性作用的能力,其比色试验建立在活细胞降解MTT的基础上,用炭疽吸附疫苗(AVA)制备的人和家兔抗血清验证这个试验结果。试验结果显示高水平的重复性和复现性,尤其是     

重组人乳头瘤病毒6型病毒样颗粒诱导中和抗体

为研究重组病毒样颗粒（virus-like particle,VLP)免疫血清的抗感染作用,用重组杆状病毒在昆虫细胞中表达制备的人乳头瘤病毒6型（human papillomavirus type 6,HPV-6)L1 VLP的HPV－6L1＋L2 VLP免疫BALB／c小鼠,获得抗血清,ELISA法测定抗体滴度,在细胞水平和裸鼠异源组织移植模型中评价了免疫血清的中和病毒抗感染作用。VLP诱导了高滴度（＞1：10000）的血清抗体,抗血清可以特异地阻断人胚上皮细胞对VLP的摄入,并且能抑制从尖锐湿疣活检标本提取的HPV对人上皮细胞的感染。重组HPV－6VLP免疫小鼠诱导的血清抗体具有中和病毒、抑制感染的作用。提示重组VLP可以用于研制HVP预防性疫苗。     

草鱼出血病病毒多肽的免疫原性

采用中和试验比较了草鱼出血病病毒ＧＣＨＶ８７３的１１个多肽的免疫原性,确定了主要中和抗原。纯化的单个病毒多肽免疫家兔获得抗血清,多太ＶＰ１、ＶＰ５、ＶＰ６和ＶＰ９的抗血清具有中和效价,而ＶＰ２、ＶＰ３、ＶＰ４、ＶＰ８、ＶＰ１０和ＶＰ１１则不能诱生中和抗体。其中ＶＰ５的抗血清中和效价最高,因此,ＶＰ６极可能是病毒多肽中的主要中和抗原。     

基于重组荧光病毒的流式细胞术检测抗CV-A16中和抗体的研究

建立基于重组荧光病毒CV-A16-EGFP的流式快速测定CV-A16感染或免疫动物血清中和抗体效价的方法。在Vero细胞上对不同感染时间点,不同病毒接种量情况下的CV-A16-EGFP病毒的增殖特性进行分析;随后,利用流式检测不同病毒滴度下的EGFP阳性细胞数量、EGFP阳性细胞百分比(%)、及EGFP阳性细胞的平均荧光密度值,并换算出不同病毒滴度与三者之间分别的数值对应关系。最后,以平均荧光密度值作为替代判断病毒病变效应的指标,并利用流式荧光检测及传统微量中和方法对CV-A16感染恒河猴血清及CV-A16免疫的羊血清中和抗体效价进行检测,并对两种方法的检测结果进行比较。在感染后24h,不同的病毒滴度与对应的平均荧光密度值呈良好的线性关系。利用流式荧光检测的CV-A16中和抗体效价与传统的微量中和实验相比,两者检测结果具有较好的线性相关性,线性回归系数为R~2=0.8026;传统的微量中和实验检测的平均中和抗体效价略高于流式荧光检测的中和抗体效价,但是差异无统计学意义(P0.05)。利用流式荧光检测可以迅速检测CV-A16中和抗体效价,并且实验结果与传统的微量中和实验具有较好的一致性。相比与传统方法,该方法更简单、快速、灵敏,为CV-A16抗血清的中和抗体检测提供参考。     

高效价腮腺炎病毒抗血清的制备及检定

目的制备高效价腮腺炎病毒抗血清,用于麻腮、麻腮风、麻腮风水痘联合疫苗的病毒滴定及鉴别试验等指标的检定。方法将腮腺炎病毒ME株接种于SPF鸡胚尿囊腔中,优化病毒制备工艺条件,收获高滴度病毒原液,制备免疫抗原;采用皮下多点注射法免疫SPF豚鼠,制备抗血清并对其进行中和效价、中和能力以及特异性干扰试验的检定。结果 ME株腮腺炎病毒以102倍稀释接种鸡胚尿囊腔,培养5 d经-20℃预冷1 h后,收获的尿囊液病毒滴度最高;以其免疫豚鼠所制备的抗血清平均中和效价达1∶3 276,高于鸡抗腮腺炎病毒血清;当豚鼠抗腮腺炎病毒血清稀释度为1∶320时,可完全中和1 000 CCID50/m L的腮腺炎病毒;豚鼠抗腮腺炎病毒血清对Vero细胞、RK-13细胞及2BS细胞的生长,均未见干扰及细胞毒性作用;豚鼠抗腮腺炎病毒血清对异种病毒(麻疹病毒、风疹病毒和水痘病毒)滴度的干扰试验显示,各病毒滴度其试验组与对照组的差值均0.50 lg CCID50/m L,表明豚鼠抗腮腺炎病毒血清对麻疹病毒、风疹病毒和水痘病毒的滴度均无干扰;豚鼠抗腮腺炎病毒血清及鸡抗腮腺炎病毒血清对麻腮风水痘联合疫苗各病毒滴度均无干扰,且两种抗血清之间差异无统计学意义(P0.05)。结论采用优化后的病毒制备工艺条件及免疫方法,可获得较高效价的抗腮腺炎病毒血清,经检定和验证,均符合含腮腺炎成分疫苗检定抗血清使用要求。     

狂犬病毒蚀斑方法的建立

我们用CTN-1狂犬病毒二倍作细胞适应株[1]经蚀斑纯化而获得的CTN-2病毒株在BHK-21单层细胞培养建立了狂犬病毒的简易蚀斑技术。用连续10倍稀释的病毒悬液接种BHK-21细胞而产生的蚀斑数呈10倍规律的减少。该蚀斑技术用于蚀斑减少中和试验测定不同国际单位(IU)效价的抗狂犬病血清与原抗血清(IU)效价均高低成正比。用蚀斑中和试验测定了七批我国生产的人用精制抗狂犬病血清的IU效价与原抗血清IU效价的高低是相符的。     

Pichia pastoris酵母中表达人源中和性抗甲型肝炎病毒scFv-Fc融合抗体的研究

为了探讨人源抗甲型肝炎（甲肝）病毒scFv—Fc融合抗体在酵母中的表达特性,将获得的人源抗甲肝病毒中和性单链可变区抗体（scFv抗体）基因克隆入含信号肽及人IgG1Fc抗体基因的酵母细胞表达载体中,获得了一株中和性人源抗甲肝病毒pPiscFv—FcHA16融合抗体的分泌表达,并对表达产物进行了纯化。同时对表达产物的生物学特性进行了一系列鉴定。表达的pPiscFv—FcHA16融合抗体为具有不同糖基化形式的同源二聚体,与相应的CHO细胞表达的IgG抗体相比,pPiscFv—FcHA16融合抗体仍保持很好的抗原结合活性,以及与中和性鼠抗甲肝病毒单克隆抗体的竞争抑制能力。同时也保持了对甲肝病毒的体外中和活性。这些结果表明,在酵母中表达的单链可变区（scFv）与IgG1Fc区的融合抗体具有很好的生物学活性,有希望用做体外诊断,用纯化相应的抗原,或者可能用于体内预防与治疗。     

双链核糖核酸病毒的研究 Ⅲ.水稻普通矮缩病毒与家蚕细胞质多角体病毒间的免疫交叉反应

水稻普通矮缩病毒(RDV)的兔抗血清能分别与家蚕细胞质多角体病毒(CPV)颗粒及其双链RNA在免疫对流电泳中产生沉淀线。用水稻普通矮缩病毒的抗血清中和后的家蚕CPV的感染力与对照相比降低二个数量级。     

抗对虾白斑综合症病毒单链抗体P1D3基因在毕赤酵母中的分泌表达

为了将可中和对虾白斑综合症病毒(WSSV)的单链抗体P1D3在酵母中实现表达,以原核表达载体M13噬菌粒为模板,设计带有SnaBⅠ和EcoRⅠ酶切位点的特异性引物,通过PCR方法扩增P1D3基因。经过酶切、连接反应将该基因连入大肠杆菌-酵母穿梭质粒pPIC9K上。重组质粒pPIC9K-scFvP1D3经BglⅡ线性化后,用电转化的方法转入毕赤酵母(Pichiapastoris)GS115中。通过PCR和DNA测序,挑选和鉴定阳性克隆。经甲醇诱导,P1D3在酵母中获得分泌表达。ELISA实验结果表明,酵母表达上清液中的单链抗体具有较高的WSSV结合活性,而且其活性要高于大肠杆菌所表达抗体的活性。表达条件优化后,单链抗体在酵母中最高表达量可达302mg/L,为开展对虾被动免疫研究提供了新的抗体来源。     

Identification of a WSSV neutralizing scFv antibody by phage display technology and in vitro screening

White spot syndrome virus (WSSV) is one of the most significant viral pathogens causing high mortality and economic damage in shrimp aquaculture. Although intensive efforts were undertaken to detect and characterize WSSV infection in shrimp during the last decade, we still lack methods either to prevent or cure white spot disease. Most of the studies on neutralizing antibodies from sera have been performed using in vivo assays. For the first time, we report use of an in vitro screening method to obtain a neutralizing scFv antibody against WSSV from a previously constructed anti-WSSV single chain fragment variable region (scFv) antibody phage display library. From clones that were positive for WSSV by ELISA, 1 neutralizing scFv antibody was identified using an in vitro screening method based on shrimp primary lymphoid cell cultures. The availability of a neutralizing antibody against the virus should accelerate identification of infection-related genes and the host cell receptor, and may also enable new approaches to the prevention and cure of white spot disease.     

Vp28 of shrimp white spot syndrome virus is involved in the attachment and penetration into shrimp cells

White spot disease (WSD) is caused by the white spot syndrome virus (WSSV), which results in devastating losses to the shrimp farming industry around the world. However, the mechanism of virus entry and spread into the shrimp cells is unknown. A binding assay in vitro demonstrated VP28-EGFP (envelope protein VP28 fused with enhanced green fluorescence protein) binding to shrimp cells. This provides direct evidence that VP28-EGFP can bind to shrimp cells at pH 6.0 within 0.5 h. However, the protein was observed to enter the cytoplasm 3 h post-adsorption. Meanwhile, the plaque inhibition test showed that the polyclonal antibody against VP28 (a major envelope protein of WSSV) could neutralize the WSSV and block an infection with the virus. The result of competition ELISA further confirmed that the envelope protein VP28 could compete with WSSV to bind to shrimp cells. Overall, VP28 of the WSSV can bind to shrimp cells as an attachment protein, and can help the virus enter the cytoplasm.     

一种抗对虾白斑综合症病毒(WSSV)线性抗原表位单链抗体的筛选

对虾白斑综合症病毒(WSSV)是全世界对虾养殖业最主要的病原体之一, 虽然对该病毒的研究已较为深入, 但目前仍无有效的防治方法。本研究应用噬菌体展示技术, 构建了抗变性WSSV的单链抗体噬菌体展示文库, 分别以WSSV病毒粒子和原核表达的囊膜蛋白VP28为靶分子对该文库进行淘选。经过数轮淘选后, 得到5个能特异识别WSSV的单链抗体, 且首次获得了能特异识别WSSV线性抗原表位的单链抗体P75E8。并通过免疫胶体金电镜分析, 对5种单链抗体对应在病毒粒子上的表位进行了定位。为获取识别多种WSSV抗原的抗体提供了新的方法路线, 也为获取特异性识别线性表位的单链抗体提供了一种新的淘选技巧。     

Antibody-resistant spread of vesicular stomatitis virus infection in cell lines of epithelial origin.

In MDCK cells, vesicular stomatitis virus (VSV) buds exclusively from the basolateral plasma membranes beneath tight junctions, whereas influenza virus forms only at the free apical surface. Anti-VSV antiserum did not prevent the formation of plaques on MDCK cell monolayers infected with VSV, whereas plaque formation in BHK-21 cells was completely inhibited by such antiserum. Under similar conditions, homologous antiserum completely prevented plaque formation by influenza virus on MDCK cells. In several other epithelioid cell lines, VSV also formed plaques in the presence of specific antiserum. These results suggest that VSV receptors are present on basolateral membranes in the cells studied and that junctional complexes present between cells may exclude antibody from intercellular spaces and thus permit the lateral spread of virus infection in the presence of neutralizing antibody.     

抗对虾白斑综合症病毒的单链抗体A1的表达和生物化学特性

用噬菌体展示技术制备了抗对虾白斑综合症病毒(WSSV)的单链抗体A1。该抗体在30℃培养条件下诱导表达20h后,其蛋白表达量可达总菌体蛋白的3.67%。用亲和层析柱和SephadexG-100层析柱可将单链抗体A1纯化为一条单电泳条带,其分子量约为31.5kD。用等电聚焦电泳测定,其等电点为pH5.8。ELISA测定表明冻干的单链抗体A1在室温储藏4年后与WSSV结合仍具有较高的活力。       

Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells.

A rabbit antiserum has been prepared against the B95-8 transforming strain of EBV. The antiserum has a high virus neutralizing titer (approximately 1:1000) against both the marmoset B95-8 EBV and the human P3HR-1 EBV. The neutralizing antibodies may be absorbed completely with EBV producer cell lines, but not with nonproducer cell lines or producer cell lines treated with phosphonoacetic acid (PAA) so as to be nonproducer. After repeated absorption with PAA-treated B95-8, the serum remains reactive with the membranes of producer cell lines as judged by immunofluorescence or the 125I--Staphylococcal protein A radioimmunoassay. Thus the neutralizing antigens are expressed on the membranes of producer cell lines and may be purified from this source using the serum and 125I--Staph A binding as an assay. The ability of the serum to differentiate between producer and nonproducer cells by means of cell surface determinants has been exploited to achieve a separation of these two populations from the same culture. Immunoprecipitation by the protein A technique shows that the serum recognizes two polypeptides from producer cells of approximate molecular weights 150,000 and 75,000.     

Chromosomal sites of integration of simian virus 40 DNA sequences mapped by in situ hybridization in two transformed hybrid cell lines.

The neutralizing characteristics of monoclonal antibodies directed to four antigenic sites on the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus were determined. Neutralization by each antibody resulted in a persistent fraction of nonneutralized virus which varied from 1 to 17% depending on the hemagglutinin-neuraminidase site recognized, but not on the antibody. The addition of antibodies to all four sites on the hemagglutinin-neuraminidase glycoprotein was required to give a level of neutralization comparable with that obtained with polyclonal mouse antiserum. The high persistent fractions were not due to viral aggregates, a high level of variants in the virus stock, the use of insufficient antibody, low antibody avidity, or an effect peculiar to the use of the chicken cells as host. The addition of rabbit anti-mouse immunoglobulin to the persistent fraction left by any of the antibodies resulted in a further reduction in infectivity, often by as much as two logs. Thus, some viral particles are capable of binding antibody while retaining their infectivity. The implications of these findings to the mechanism of neutralization are discussed.     

Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Characterization of biological and immunological properties of human immunodeficiency virus type 1 (HIV-1) is critical to developing effective therapies and vaccines for AIDS. With the use of a novel CD4+ T-cell line (PM-1) permissive to infection by both monocytotropic (MT) and T-cell-tropic virus types, we present a comparative analysis of the immunological properties of a prototypic primary MT isolate of HIV-1 strain JR-CSF (MT-CSF) with those of a T-cell-tropic variant (T-CSF) of the same virus, which emerged spontaneously in vitro. The parental MT-CSF infected only PM-1 cells and was markedly resistant to neutralization by sera from HIV-1-infected individuals, rabbit antiserum to recombinant MT-CSF gp120, and anti-V3 monoclonal antibodies. The T-CSF variant infected a variety of CD4+ T-cell lines, contained positively charged amino acid substitutions in the gp120 V3 region, and was highly sensitive to antibody neutralization. Neutralization and antibody staining of T-CSF-expressing cells were significantly inhibited by HIV-1 V3 peptides; in contrast, the MT strain showed only weak V3-specific binding of polyclonal and monoclonal antibodies. Exposure of PM-1 cells to a mixture of both viruses in the presence of human anti-HIV-1 neutralizing antiserum resulted in infection with only MT-CSF. These results demonstrate that although the V3 region of MT viruses is immunogenic, the target epitopes in the V3 principal neutralizing domain on the membrane form of the MT envelope appear to be cryptic or hidden from blocking antibodies.     

Production of anti-rat islet cell surface antibody in guinea pigs

Anti-rat islet serum was prepared in guinea pigs by multiple subcutaneous inoculations of rat islets homogenates emulsified in complete Freund's adjuvant (CFA). The anti-rat islet serum was cytotoxic against rat spleen cells in the presence of complement and the nonspecific antibodies were observed with homogenates of rat livers and spleens. After absorption, the serum lost the cytotoxicity against the rat spleen cells yet showed specific cytotoxicity against the rat islet cells. The binding capacity of anti-rat islet antibody was determined by the indirect immunofluorescence test using FITC conjugated rabbit anti-guinea pig IgG serum. As the guinea pig anti-rat islet serum contained anti-insulin antibody, the role of this antibody in this cytotoxic activity and surface immunofluorescence was studied. However, the anti-insulin antibody used as the control showed neither cytotoxicity nor surface immunofluorescence. After neutralizing the anti-insulin antibody in the antiserum with insulin, the serum remained cytotoxic to the rat islet cells and a surface immunofluorescence appeared. These data show that specific anti-rat islet cell surface antibody can be produced in guinea pigs by multiple inoculations of rat islets homogenates with CFA.